MCID: IMP006
MIFTS: 45

Impulse Control Disorder

Categories: Mental diseases

Aliases & Classifications for Impulse Control Disorder

MalaCards integrated aliases for Impulse Control Disorder:

Name: Impulse Control Disorder 12 15
Disruptive, Impulse Control, and Conduct Disorders 44 70

Classifications:



External Ids:

Disease Ontology 12 DOID:10937
ICD9CM 34 312.30
MeSH 44 D007174
NCIt 50 C34723
SNOMED-CT 67 192098008
ICD10 32 F63.9
UMLS 70 C0021122

Summaries for Impulse Control Disorder

Disease Ontology : 12 A disease of mental health that involves a failure to resist an impulsive act or behaviour that may be harmful to self or others.

MalaCards based summary : Impulse Control Disorder, also known as disruptive, impulse control, and conduct disorders, is related to intermittent explosive disorder and trichotillomania. An important gene associated with Impulse Control Disorder is ANKK1 (Ankyrin Repeat And Kinase Domain Containing 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Transmission across Chemical Synapses. The drugs Ethanol and Pramipexole have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and liver, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 73 Impulse-control disorder (ICD) is a class of psychiatric disorders characterized by impulsivity -... more...

Related Diseases for Impulse Control Disorder

Diseases related to Impulse Control Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 172)
# Related Disease Score Top Affiliating Genes
1 intermittent explosive disorder 31.6 SLC6A4 MAOA HTR2A HTR1A COMT
2 trichotillomania 31.5 SLITRK5 SLITRK1 MAOA HOXB8 DRD4 DLGAP3
3 oppositional defiant disorder 31.5 SLC6A4 SLC6A3 MAOA HTR2A DRD4 DRD2
4 kleptomania 31.2 SLC6A4 MAOA HTR1A GYPE DRD2 DLGAP3
5 stuttering 30.1 SLC6A3 GYPE DRD2
6 premature ejaculation 30.0 SLC6A4 SLC6A3 HTR1A COMT
7 pathological gambling 30.0 SLC6A4 SLC6A3 OPRM1 MAOB MAOA HTR2A
8 fibromyalgia 29.9 SLC6A4 OPRM1 HTR2A COMT
9 withdrawal disorder 29.8 SLC6A3 OPRM1 HTR1A GRIN2B
10 bulimia nervosa 29.7 SLC6A4 MAOA HTR2A DRD4 DRD2 COMT
11 social phobia 29.6 SLC6A4 MAOA HTR2A HTR1A DRD2 COMT
12 movement disease 29.5 SLC6A3 MAOB HTR1A GYPE GRN DRD3
13 bipolar i disorder 29.5 SLC6A4 HTR2A HTR1A DRD2 DRD1 COMT
14 borderline personality disorder 29.4 SLC6A4 SLC6A3 MAOA HTR2A HTR1A DRD2
15 restless legs syndrome 29.4 SLC6A4 SLC6A3 MAOB MAOA DRD4 DRD3
16 sleep disorder 29.4 SLC6A4 SLC6A3 HTR2A HTR1A GRIN2B COMT
17 bestiality 29.3 SLC6A3 MAOA HTR2A DRD4 DRD3 DRD2
18 antisocial personality disorder 29.2 SLC6A4 SLC6A3 MAOB MAOA HTR2A DRD4
19 personality disorder 29.0 SLC6A4 SLC6A3 MAOB MAOA HTR2A HTR1A
20 dystonia 28.9 SLC6A3 MAOB HTR2A GRN GRIN2B DRD3
21 parkinson disease, late-onset 28.8 SLC6A4 SLC6A3 MAOB MAOA HTR2A HTR1A
22 substance abuse 28.6 SLC6A4 SLC6A3 OPRM1 MAOA HTR2A HTR1A
23 bipolar disorder 28.6 SLC6A4 SLC6A3 MAOA HTR2A HTR1A GRIN2B
24 attention deficit-hyperactivity disorder 28.4 SLC6A4 SLC6A3 OPRM1 MAOB MAOA HTR2A
25 alcohol use disorder 28.3 SLC6A4 SLC6A3 OPRM1 HTR2A HTR1A GRIN2B
26 psychotic disorder 27.8 SLC6A4 SLC6A3 OPRM1 MAOB MAOA HTR2A
27 pyromania 11.4
28 kluver-bucy syndrome 11.1
29 alcohol-induced mental disorder 10.3 SLC6A4 DRD2
30 dependent personality disorder 10.3 MAOA DRD4
31 taqi polymorphism 10.3 DRD2 ANKK1
32 pedophilia 10.3 MAOA GRN
33 traumatic brain injury 10.3 DRD2 COMT ANKK1
34 flying phobia 10.3 MAOA COMT
35 exhibitionism 10.3 MAOA DRD4
36 sexual sadism 10.3 MAOA COMT
37 early-onset schizophrenia 10.3 DRD2 DRD1
38 amphetamine abuse 10.3 SLC6A4 SLC6A3
39 polysubstance abuse 10.3 DRD3 DRD2 COMT
40 color agnosia 10.3 SLITRK1 GRN
41 conversion disorder 10.2 HTR2A COMT
42 postencephalitic parkinson disease 10.2 SLC6A3 MAOB
43 parkinsonism 10.2
44 rem sleep behavior disorder 10.2
45 corneal dystrophy, lisch epithelial 10.2 MAOA HTR1A
46 multiple system atrophy 1 10.2 SLC6A3 MAOB DRD2
47 alcoholic psychosis 10.2 SLC6A4 SLC6A3 HTR2A
48 barbiturate dependence 10.2 SLC6A4 OPRM1
49 striatonigral degeneration 10.2 SLC6A3 DRD2 DRD1
50 hyperprolactinemia 10.2 HTR2A DRD4 DRD2

Comorbidity relations with Impulse Control Disorder via Phenotypic Disease Network (PDN):


Schizophreniform Disorder

Graphical network of the top 20 diseases related to Impulse Control Disorder:



Diseases related to Impulse Control Disorder

Symptoms & Phenotypes for Impulse Control Disorder

MGI Mouse Phenotypes related to Impulse Control Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 COMT DLGAP3 DRD1 DRD2 DRD3 DRD4
2 homeostasis/metabolism MP:0005376 10.03 COMT DRD1 DRD2 DRD3 DRD4 GRIN2B
3 integument MP:0010771 9.61 DLGAP3 DRD1 DRD2 GRN HOXB8 OPRM1
4 nervous system MP:0003631 9.55 COMT DLGAP3 DRD1 DRD2 DRD3 DRD4

Drugs & Therapeutics for Impulse Control Disorder

Drugs for Impulse Control Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
3
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
4
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 497540 5095
5
Carbidopa Approved Phase 4 28860-95-9 34359
6
Levodopa Approved Phase 4 59-92-7 6047
7
Citalopram Approved Phase 4 59729-33-8 2771
8
Sertraline Approved Phase 4 79617-96-2 68617
9
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
10
Naratriptan Approved, Investigational Phase 4 143388-64-1, 121679-13-8 4440
11
Dexetimide Withdrawn Phase 4 21888-98-2
12 Narcotics Phase 4
13 Narcotic Antagonists Phase 4
14 Cardiotonic Agents Phase 4
15 Dopamine Agents Phase 4
16 Sympathomimetics Phase 4
17 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
18 Antidepressive Agents Phase 4
19 Serotonin Uptake Inhibitors Phase 4
20 Antihypertensive Agents Phase 4
21 Adrenergic alpha-Agonists Phase 4
22 Adrenergic Agents Phase 4
23 Adrenergic Agonists Phase 4
24 Neurotransmitter Agents Phase 4
25 Vasoconstrictor Agents Phase 4
26 Serotonin Receptor Agonists Phase 4
27 Serotonin 5-HT1 Receptor Agonists Phase 4
28
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
29
Acetylcysteine Approved, Investigational Phase 3 616-91-1 12035
30
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
31
Risperidone Approved, Investigational Phase 3 106266-06-2 5073
32 N-monoacetylcystine Phase 3
33 Psychotropic Drugs Phase 3
34 Antipsychotic Agents Phase 3
35 Dopamine Antagonists Phase 3
36
Nalmefene Approved, Investigational, Withdrawn Phase 2 55096-26-9 5284594
37
Nicotine Approved Phase 2 54-11-5 942 89594
38
Fluoxetine Approved, Vet_approved Phase 2 54910-89-3 3386
39
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
40
Memantine Approved, Investigational Phase 2 19982-08-2 4054
41
Clonidine Approved Phase 2 4205-90-7 2803
42
Pimavanserin Approved, Investigational Phase 2 706779-91-1 16058810
43
Quinidine Approved, Investigational Phase 2 56-54-2 441074
44 Cytochrome P-450 Enzyme Inhibitors Phase 2
45 Anticonvulsants Phase 2
46 Excitatory Amino Acid Antagonists Phase 2
47 Vasopressins Phase 1, Phase 2
48 SRX246 Phase 1, Phase 2
49 Hormones Phase 1, Phase 2
50 Arginine Vasopressin Phase 1, Phase 2

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
2 The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy Completed NCT01683253 Phase 4 Levodopa/Carbidopa(200mg/50mg);Dopaminergic Agonists
3 Escitalopram for the Treatment of Self-Injurious Skin Picking Completed NCT00115011 Phase 4 Escitalopram
4 Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania Completed NCT00118014 Phase 4 Sertraline
5 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Completed NCT02048241 Phase 4 Intuniv
6 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated NCT00282165 Phase 4 naratriptan;placebo
7 Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's Disease Unknown status NCT03146130 Phase 3
8 Effects of Risperidone on Cognitive-Motor Performance and Motor Movements in Chronically Medicated Children Completed NCT00399698 Phase 3 Risperdal
9 Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study Unknown status NCT02934919 Phase 2 Nalmefene
10 An Exploratory, Placebo-Controlled, Crossover Study to Examine the Safety and Activity of SXC-2023 to Improve Behavioral Dynamics in Non-Treatment Seeking Adults Undergoing Acute Nicotine Withdrawal Completed NCT03887429 Phase 2 SXC-2023;Placebos
11 Fluoxetine and Divalproex: Treatment Correlates in IED Completed NCT00078754 Phase 2 Fluoxetine;Divalproex;Placebo
12 A Double-Blind, Placebo-Controlled Study of Naltrexone in Kleptomania Completed NCT00332579 Phase 2 Naltrexone;Placebo
13 A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With Intermittent Explosive Disorder Completed NCT00127400 Phase 2
14 Memantine Treatment of Kleptomania: An Open-Label Study Completed NCT00880685 Phase 2 Memantine
15 Individual Cognitive Behavioral Psychotherapy for Intermittent Explosive Disorder Completed NCT00667212 Phase 2
16 An Exploratory Phase II Study to Determine the Safety, Tolerability and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults With Diagnostic and Statistical Manual Version 5 (DSM-5) Intermittent Explosive Disorder (IED) Completed NCT02055638 Phase 1, Phase 2 SRX246;Placebo
17 Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease: A Pilot Double Blind Randomized Trial Recruiting NCT03552068 Phase 2 placebo;Clonidine
18 Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease Recruiting NCT03947216 Phase 2 Active drug: pimavanserin 17mg (2 strength tablets);Placebo: 2 tablets containing same excipients except active compound
19 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Intermittent Explosive Disorder (IED) Terminated NCT03420222 Phase 2 AVP-786;Placebo
20 N-Acetylcysteine in the Treatment of Deliberate Self-Harm in Adolescents: An Open Label Pilot Study Completed NCT01111734 Phase 1 fMRI
21 A Single-blind, Randomized, Placebo Controlled, Two-period Crossover fMRI Study to Investigate the Effects of the D3 Antagonist GSK598809 on Neural and Behavioural Responses to Food Reward and Reinforcement After a Single Oral Dose of GSK598809 in Overweight and Obese Subjects. Completed NCT01039454 Phase 1 GSK598809 Capsules;GSK598809 Placebo Capsules
22 Effects of Non-invasive Brain on Decision-making in Impulse Control Disorders Unknown status NCT02927002
23 Circadian Character of Food Compulsions and Impulses Control Disorders in Parkinsonian Patients With and Without Resting Leg Syndrome Unknown status NCT03818243
24 Exploration of Mesocorticolimbic Pathway in Impulse Control Disorders in Parkinson's Disease: Study Using Tensor Diffusion Imaging and Tractography. Unknown status NCT02796040
25 Psychosocial Risk- and Protective Factors of Secondary School Dropout in Luxembourg: an Exploratory Case-control Study Unknown status NCT01354236
26 Assessment of Longitudinal Functional Magnetic Resonance Imaging (fMRI) as a Brain Measure for Impulsivity in a Borderline Personality Disorder (BPD) Model Completed NCT02755181
27 Fingerprinting of Impulsivity in Four Diagnostic and Statistical Manual of Mental Disorders, Version 5 (DSM-5) Psychiatric Disorders That Have Been Clinically Associated With Impulsivity Using a Battery of Questionnaires and Behavioral Laboratory Tests Completed NCT02722174
28 A Cross-sectional, Retrospective Screening and Case-control Study Examining the Frequency of, and Risk Factors Associated With, Impulse Control Disorders in Parkinson's Disease Patients Treated With MIRAPEX® (Pramipexole) and Other Anti-parkinson Agents (DOMINION Study) Completed NCT00617019
29 Behavioural Addiction and Genetics in Parkinson's Disease Completed NCT02319395
30 Role of the Serotoninergic System in Impulse Control Disorders in Parkinson's Disease Recruiting NCT03970239 Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin);Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)
31 Modification and Evaluation of the DECIDE Intervention to Improve Parent-provider Interactions in Low-income Parents of Adolescents With Disruptive Impulse Control, and Conduct Disorder Recruiting NCT04445155
32 Attention and Interpretation Bias Modification for Aggression Difficulties Not yet recruiting NCT04819230

Search NIH Clinical Center for Impulse Control Disorder

Cochrane evidence based reviews: disruptive, impulse control, and conduct disorders

Genetic Tests for Impulse Control Disorder

Anatomical Context for Impulse Control Disorder

MalaCards organs/tissues related to Impulse Control Disorder:

40
Brain, Skin, Liver, Subthalamic Nucleus, Eye, Cortex, Prefrontal Cortex

Publications for Impulse Control Disorder

Articles related to Impulse Control Disorder:

(show top 50) (show all 425)
# Title Authors PMID Year
1
Exploring Nonmotor Neuropsychiatric Manifestations of Parkinson Disease in a Comprehensive Care Setting. 61
32242493 2021
2
From the urge to see one's own blood to the urge to drink it: can hemomania be specified as an impulse control disorder? Two case reports. 61
33682634 2021
3
Effects of pollution on adolescent mental health: a systematic review protocol. 61
33773602 2021
4
Birds of a Feather Flock Together: Disadvantageous Decision Making in Augmented Restless Legs Syndrome Patients with and without Impulse Control Disorders. 61
33802756 2021
5
The relationship between exposure to general anesthetic agents and the risk of developing an impulse control disorder. 61
33493656 2021
6
Impulse control disorder under dopaminergic agonists revealed by acts of violence against animals. 61
32778341 2021
7
No Change in Prevalence of Impulse Control Disorder Behaviors in Parkinson's Disease During the Last Decade. 61
33232532 2021
8
Characteristics of Patients with Late-Stage Parkinsonism Who are Nursing Home Residents Compared with those Living at Home. 61
32723531 2021
9
Risk of Substance Use Disorder and Its Associations With Comorbidities and Psychotropic Agents in Patients With Autism. 61
33394019 2021
10
Consideration of Clinician and Researcher Opinions on the Parameters of Nonsuicidal Self-Injury Disorder Diagnostic Criteria. 61
33352417 2021
11
[Descriptive analysis of the admission of minors into a psychiatric unit]. 61
32386933 2021
12
Cannabis for Restless Legs Syndrome. 61
33537945 2021
13
Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study. 61
33314003 2020
14
[Clinical experience in the treatment of motor fluctuations in Parkinson's disease. Delphi consensus of a group of experts in movement disorders]. 61
33205387 2020
15
Visual Hallucinations and Impulse Control Disorder in Parkinson's Disease. 61
32658290 2020
16
Depression in Parkinson's disease: Perspectives from an Australian cohort. 61
33065812 2020
17
123I-Ioflupane dopamine transporter imaging (DaTSCAN) appearances in relation to emotional responsiveness, impulsivity and olfaction in suspected Parkinsonian syndrome. 61
32826621 2020
18
Gambling in adolescence: a narrative review of the last 20 years. 61
32634072 2020
19
Is Rapid Eye Movement Sleep Behavior Disorder a Risk Factor for Impulse Control Disorder in Parkinson Disease? 61
32468593 2020
20
Young-Onset Parkinson's Disease with Impulse Control Disorder Due to Novel Variants of F-Box Only Protein 7. 61
32894901 2020
21
LCIG in treatment of non-motor symptoms in advanced Parkinson's disease: Review of literature. 61
32677345 2020
22
Association of MAPT subhaplotypes with clinical and demographic features in Parkinson's disease. 61
32767721 2020
23
Kleptomania as a neglected disorder in psychiatry. 61
32401643 2020
24
Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder. 61
32761061 2020
25
Impulse control and related behaviors in Parkinson's disease with dementia. 61
32048392 2020
26
Altered core networks of brain connectivity and personality traits in internet gaming disorder. 61
32592635 2020
27
The development of the Compulsive Sexual Behavior Disorder Scale (CSBD-19): An ICD-11 based screening measure across three languages. 61
32609629 2020
28
A qualitative research of adolescents with behavioral problems about their experience in a dialectical behavior therapy skills training group. 61
32429886 2020
29
Impulse control disorder-linked hypersexuality complicated by disseminated gonococcal infection in a patient with Parkinson's disease. 61
32139181 2020
30
Prevalence of comorbid psychiatric disorders among people with autism spectrum disorder: An umbrella review of systematic reviews and meta-analyses. 61
32203749 2020
31
Gambling and substance use: Comorbidity and treatment implications. 61
31881248 2020
32
Validation of the Korean Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale. 61
32319241 2020
33
Woolly Hair Nevus with Trichotillomania in a 9-Year-Old Boy: A Rare Case Association. 61
32684682 2020
34
Functional inhibitory control dynamics in impulse control disorders in Parkinson's disease. 61
31710401 2020
35
Linking brain activity during sequential gambling to impulse control in Parkinson's disease. 61
32688307 2020
36
Contributing Factors and Evolution of Impulse Control Disorder in the Luxembourg Parkinson Cohort. 61
33281714 2020
37
Corrigendum: Contributing Factors and Evolution of Impulse Control Disorder in the Luxembourg Parkinson Cohort. 61
33510710 2020
38
Altruistic Punishment and Impulsivity in Parkinson's Disease: A Social Neuroscience Perspective. 61
32792921 2020
39
How has Internet Addiction been Tracked Over the Last Decade? A Literature Review and 3C Paradigm for Future Research. 61
33456731 2020
40
Serial Cats Maiming Reveals Impulse Control Disorder Under Dopaminergic Agonists. 61
31970229 2020
41
Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study. 61
31883082 2020
42
Functional Analysis of the SIM1 Variant p.G715V in 2 Patients With Obesity. 61
31872862 2020
43
Impulsivity Relates to Relative Preservation of Mesolimbic Connectivity in Patients with Parkinson Disease. 61
32361415 2020
44
Hypermethylation-associated downregulation of microRNA-4456 in hypersexual disorder with putative influence on oxytocin signalling: A DNA methylation analysis of miRNA genes. 61
31542994 2020
45
We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database. 61
33343407 2020
46
Trichotillomania is more related to Tourette disorder than to obsessive-compulsive disorder. 61
31576938 2020
47
Response Inhibition and Emotional Regulation in the Patients with Attention-Deficit/Hyperactivity Disorder and Comorbidity of Disruptive, Impulse-Control, and Conduct Disorders. 61
31760718 2019
48
COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation. 61
31179586 2019
49
Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. 61
31447415 2019
50
A Stage-Based Approach to Therapy in Parkinson's Disease. 61
31434341 2019

Variations for Impulse Control Disorder

Expression for Impulse Control Disorder

Search GEO for disease gene expression data for Impulse Control Disorder.

Pathways for Impulse Control Disorder

Pathways related to Impulse Control Disorder according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.48 OPRM1 HTR2A HTR1A GRIN2B DRD4 DRD3
2
Show member pathways
12.89 SLC6A4 SLC6A3 MAOA GRIN2B DLGAP3 COMT
3
Show member pathways
12.72 SLC6A3 MAOB MAOA GRIN2B DRD2 DRD1
4
Show member pathways
12.28 SLC6A3 MAOB MAOA GRIN2B DRD4 DRD3
5 12.25 GRIN2B DRD4 DRD3 DRD2 DRD1
6 12.2 HTR1A GRIN2B DRD2 DRD1
8 12.06 SLC6A4 MAOA HTR2A HTR1A
9 11.86 SLC6A4 MAOB MAOA HTR2A HTR1A
10
Show member pathways
11.85 GRIN2B DRD4 DRD2 DRD1
11
Show member pathways
11.81 SLC6A3 MAOB MAOA GRIN2B DRD2 DRD1
12 11.8 HTR2A DRD4 DRD3
13
Show member pathways
11.79 DRD4 DRD3 DRD2
14 11.7 HTR2A DRD2 DRD1
15
Show member pathways
11.67 HTR2A HTR1A DRD4 DRD3 DRD2 DRD1
16
Show member pathways
11.66 MAOB MAOA COMT
17
Show member pathways
11.35 SLC6A4 SLC6A3 MAOA
18 11.12 SLC6A4 MAOA HTR2A HTR1A
19
Show member pathways
11.04 SLC6A4 SLC6A3 MAOA COMT
20
Show member pathways
10.81 MAOB MAOA COMT
21 10.76 MAOB MAOA COMT
22
Show member pathways
10.71 MAOB MAOA
23
Show member pathways
10.68 SLC6A4 SLC6A3 MAOB MAOA HTR1A DRD4

GO Terms for Impulse Control Disorder

Cellular components related to Impulse Control Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.39 SLITRK5 SLITRK1 SLC6A4 SLC6A3 OPRM1 MAOB
2 integral component of membrane GO:0016021 10.31 SLITRK5 SLITRK1 SLC6A4 SLC6A3 OPRM1 MAOB
3 plasma membrane GO:0005886 10.22 SLITRK5 SLITRK1 SLC6A4 SLC6A3 OPRM1 HTR2A
4 cell junction GO:0030054 10 SLITRK1 SLC6A4 HTR2A GRIN2B DRD1 DLGAP3
5 integral component of plasma membrane GO:0005887 10 SLC6A4 SLC6A3 OPRM1 HTR2A HTR1A GYPE
6 glutamatergic synapse GO:0098978 9.93 SLITRK1 HTR2A DRD4 DRD3 DRD2 DLGAP3
7 dendrite GO:0030425 9.91 OPRM1 HTR2A HTR1A DRD4 DRD2 DRD1
8 axon GO:0030424 9.88 SLC6A3 OPRM1 HTR2A DRD2 COMT
9 GABA-ergic synapse GO:0098982 9.67 SLITRK1 DRD3 DRD2
10 integral component of presynaptic membrane GO:0099056 9.55 SLC6A4 SLC6A3 OPRM1 HTR2A DRD2
11 dopaminergic synapse GO:0098691 9.51 SLC6A3 DRD2
12 integral component of postsynaptic membrane GO:0099055 9.35 SLC6A4 SLC6A3 OPRM1 HTR2A DRD2
13 synapse GO:0045202 9.32 SLITRK5 SLITRK1 SLC6A4 HTR2A HTR1A GRIN2B

Biological processes related to Impulse Control Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.33 OPRM1 HTR2A HTR1A GRN DRD4 DRD3
2 G protein-coupled receptor signaling pathway GO:0007186 10.24 OPRM1 HTR2A HTR1A DRD4 DRD3 DRD2
3 chemical synaptic transmission GO:0007268 10.02 SLITRK5 HTR2A HTR1A GRIN2B DRD4
4 cellular calcium ion homeostasis GO:0006874 9.93 HTR2A DRD4 DRD3 DRD2
5 axonogenesis GO:0007409 9.89 SLITRK5 SLITRK1 DRD2
6 response to toxic substance GO:0009636 9.88 SLC6A4 MAOB DRD2
7 locomotory behavior GO:0007626 9.88 SLC6A3 DRD3 DRD2
8 response to ethanol GO:0045471 9.88 SLC6A3 OPRM1 MAOB GRIN2B DRD3 DRD2
9 synapse assembly GO:0007416 9.87 SLITRK1 DRD2 DRD1
10 excitatory postsynaptic potential GO:0060079 9.86 OPRM1 GRIN2B DRD2
11 sensory perception of pain GO:0019233 9.85 OPRM1 HTR2A HOXB8
12 social behavior GO:0035176 9.85 SLC6A4 DRD4 DRD3
13 visual learning GO:0008542 9.84 DRD3 DRD2 DRD1
14 response to cocaine GO:0042220 9.84 SLC6A3 OPRM1 DRD3 DRD2
15 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.83 DRD3 DRD2 DRD1
16 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.83 OPRM1 HTR2A HTR1A DRD4 DRD1
17 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.82 HTR2A HTR1A DRD4
18 response to morphine GO:0043278 9.82 OPRM1 DRD3 DRD2
19 adult behavior GO:0030534 9.81 SLITRK5 SLITRK1 DRD2
20 regulation of dopamine secretion GO:0014059 9.81 HTR2A DRD3 DRD2
21 arachidonic acid secretion GO:0050482 9.79 DRD4 DRD3 DRD2
22 negative regulation of protein secretion GO:0050709 9.79 DRD4 DRD3 DRD2
23 dopamine receptor signaling pathway GO:0007212 9.78 DRD4 DRD2 DRD1
24 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.77 DRD3 DRD2 DRD1
25 negative regulation of cytosolic calcium ion concentration GO:0051481 9.77 OPRM1 DRD3 DRD2
26 grooming behavior GO:0007625 9.76 SLITRK5 HOXB8 DRD2
27 neurotransmitter catabolic process GO:0042135 9.75 MAOB MAOA COMT
28 negative regulation of voltage-gated calcium channel activity GO:1901386 9.74 DRD4 DRD3 DRD2
29 vasoconstriction GO:0042310 9.73 SLC6A4 HTR1A
30 response to iron ion GO:0010039 9.73 SLC6A3 DRD2
31 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.73 HTR2A DRD3 DRD2
32 behavior GO:0007610 9.72 HTR2A HTR1A
33 neurotransmitter biosynthetic process GO:0042136 9.72 SLC6A4 SLC6A3
34 positive regulation of renal sodium excretion GO:0035815 9.72 DRD3 DRD2
35 catecholamine metabolic process GO:0006584 9.72 MAOA COMT
36 regulation of dopamine metabolic process GO:0042053 9.72 SLC6A3 HTR1A DRD4
37 G protein-coupled receptor internalization GO:0002031 9.71 DRD3 DRD2
38 striatum development GO:0021756 9.71 SLITRK5 DRD2
39 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.71 DRD4 DRD3
40 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.7 DRD3 DRD1
41 monoamine transport GO:0015844 9.7 SLC6A4 SLC6A3
42 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.7 DRD3 DRD2 DRD1
43 adenohypophysis development GO:0021984 9.69 SLC6A3 DRD2
44 behavioral response to ethanol GO:0048149 9.69 OPRM1 DRD4 DRD2
45 hyaloid vascular plexus regression GO:1990384 9.68 SLC6A3 DRD2
46 serotonin receptor signaling pathway GO:0007210 9.68 HTR2A HTR1A
47 regulation of potassium ion transport GO:0043266 9.68 DRD3 DRD2
48 cerebral cortex GABAergic interneuron migration GO:0021853 9.67 DRD2 DRD1
49 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.67 DRD3 DRD2 DRD1
50 behavioral response to cocaine GO:0048148 9.67 HTR2A DRD4 DRD3 DRD2

Molecular functions related to Impulse Control Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.87 OPRM1 HTR2A HTR1A DRD4 DRD3 DRD2
2 neurotransmitter receptor activity GO:0030594 9.63 HTR2A HTR1A DRD4
3 G protein-coupled serotonin receptor activity GO:0004993 9.54 HTR2A HTR1A DRD4
4 neurotransmitter transporter activity GO:0005326 9.48 SLC6A4 SLC6A3
5 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A4 SLC6A3
6 serotonin binding GO:0051378 9.43 SLC6A4 HTR2A HTR1A
7 primary amine oxidase activity GO:0008131 9.4 MAOB MAOA
8 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.33 DRD4 DRD3 DRD2
9 dopamine binding GO:0035240 9.26 SLC6A3 DRD4 DRD2 DRD1
10 dopamine neurotransmitter receptor activity GO:0004952 8.92 DRD4 DRD3 DRD2 DRD1

Sources for Impulse Control Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....